Depression Symptoms and Antidepressant Medicine Use in Diabetes Prevention Program Participants
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess depression markers (symptoms and antidepressant medicine use) in Diabetes Prevention Program (DPP) participants and to determine whether changes in depression markers during the course of the study were associated with treatment arm, weight change, physical activity level, or participant demographic characteristics. RESEARCH DESIGN AND METHODS—DPP participants (n = 3,187) in three treatment arms (intensive lifestyle, metformin, and placebo) completed the Beck Depression Inventory (BDI) and reported on use of antidepressant medicines at randomization and subsequently at each annual visit (average duration in study 3.2 years). RESULTS—On study entry, 10.3% of participants had BDI scores ≥11, which was used as a threshold for mild depression, 5.7% took antidepressant medicines, and 0.9% had both depression markers. During the DPP, the proportion of participants with elevated BDI scores declined (from 10.3% at baseline to 8.4% at year 3), while the proportion taking antidepressant medicines increased (from 5.7% at baseline to 8.7% at year 3), leaving the proportion with either marker unchanged. These time trends were not significantly associated with the DPP treatment arm. Depression markers throughout the study were associated with some participant demographic factors, adjusted for other factors. Men were less likely to have elevated depression scores and less likely to use antidepressant medicine at baseline (9.0% of men and 17.9% of women had at least one marker of depression) and throughout the study (P <0.0001). Those with more education were less likely to have elevated symptom scores (P = 0.0007) but more likely to be taking antidepressant medicine (P = 0.002). Non-Hispanic white participants were less likely than African Americans to have BDI scores ≥11 (P = 0.03), but white participants were more likely to be taking antidepressant medicine than any other racial/ethnic group (P <0.0001). CONCLUSIONS—DPP participation was not associated with changes in levels of depression. Countervailing trends in the proportion of DPP participants with elevated depression symptoms and the proportion taking antidepressant medicine resulted in no significant change in the proportion with either marker. The finding that those taking antidepressant medicine often do not have elevated depression symptoms indicates the value of assessing both markers when estimating overall depression rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
The Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926 · cited 2×
“Depression is more common among people with diabetes than in the general population (1, 2).”
BackgroundThe Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
Self-citationDepression and poor glycemic control: a meta-analytic review of the literature.
Lustman, P. J., Anderson, R. J., Freedland, K. E., de Groot, M., Carney, R. M., & Clouse, R. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.934 · Cited by 1,854
Association of depression and diabetes complications: a meta-analysis
de Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200107000-00015 · Cited by 1,799 · cited 1×
“People with diabetes who are depressed have higher HbA1c levels (3), more diabetes complications (4,5), and much higher general health care costs than people with diabetes who are not depressed (6,7).”
BackgroundDepression and Diabetes: Impact of Depressive Symptoms on Adherence, Function, and Costs
Ciechanowski, P. S., Katon, W. J., & Russo, J. E. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3278 · Cited by 1,465 · cited 1×
“People with diabetes who are depressed have higher HbA1c levels (3), more diabetes complications (4,5), and much higher general health care costs than people with diabetes who are not depressed (6,7).”
BackgroundEgede, L. E., Zheng, D., & Simpson, K. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.464 · Cited by 816 · cited 1×
“People with diabetes who are depressed have higher HbA1c levels (3), more diabetes complications (4,5), and much higher general health care costs than people with diabetes who are not depressed (6,7).”
BackgroundKaton (2004) · doi:10.1001/archpsyc.61.10.1042 · Cited by 737
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Lustman, P. J., Griffith, L. S., Freedland, K. E., Kissel, S. S., & Clouse, R. E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-8-199810150-00005 · Cited by 562
Levels and risks of depression and anxiety symptomatology among diabetic adults
Peyrot, M., & Rubin, R. R. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.585 · Cited by 488 · cited 3×
“Other studies have reported that depression is less common among those with more education in the general population (24–26) and perhaps also among people with diabetes who have more education (28), although a population-based study that included people with diabetes found no association between depression and educati…”
BackgroundBone Mineral Density in Women with Depression
Michelson, D., Stratakis, C., Hill, L., Reynolds, J., Galliven, E., Chrousos, G., & Gold, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351602 · Cited by 471 · cited 1×
“Some suggest that depression could increase a person’s risk of developing type 2 diabetes (13–15), either by influencing behaviors such as eating and physical activity or via increased sympathoadrenal and hypothalamic-pituitary-adrenal axis activity (16,17).”
BackgroundA Randomized Controlled Trial of Progressive Resistance Training in Depressed Elders
Singh, N. A., Clements, K. M., & Fiatarone, M. A. (1997) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/52a.1.m27 · Cited by 439
Egede, L. E., & Zheng, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.104 · Cited by 235 · cited 6×
“We found that throughout the DPP, non-Hispanic white participants were less likely to have elevated scores than African Americans and Hispanic Americans and that they were more likely to be taking antidepressant medicine than any other racial/ethnic group.”
BackgroundInfluential
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Examining a Bidirectional Association Between Depressive Symptoms and Diabetes
Golden, S. H. (2008) · JAMA · doi:10.1001/jama.299.23.2751 · Cited by 893
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
LeBlanc, E. S., O'Connor, E., Whitlock, E. P., Patnode, C. D., & Kapka, T. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00006 · Cited by 400
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Metadata
- Authors
- The Diabetes Prevention Program Research Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2005-04-01
- Volume
- 28
- Issue
- 4
- Pages
- 830-837
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W21893697
- Cited by
- 60
- References
- 14
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.